Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers

Purpose: Topical ocular drug delivery is limited by tear turnover, corneal and conjunctival barriers, efflux transporters, and poor water solubility of many drug candidates. Lipid-based nanocarriers may improve ocular bioavailability, prolong preocular residence, enhance corneal penetration, and provide controlled release.

Hypothesis: If ophthalmic drugs are formulated into lipid-based nanocarriers—emulsions, cationic emulsions, liposomes, cubosomes, niosomes, solid lipid nanoparticles, nanostructured lipid carriers, or core–shell nanoassemblies—with suitable surface modification and mucoadhesive/cationic properties, then they can mimic or interact with the tear film, reduce washout, improve corneal penetration, and enhance ocular bioavailability.

Aims: Review advantages of lipid-based nanocarriers as non-invasive topical ocular drug delivery systems. - Describe major ocular barriers: tear film, cornea, conjunctiva, blood–aqueous and blood–retinal barriers. - Summarize lipid-based carrier types: emulsions, liposomes, cubosomes, niosomes, SLNs, NLCs, and core–shell nanoassemblies. - Highlight commercially available and clinical-stage ophthalmic lipid formulations. - Discuss future perspectives for ocular lipid nanomedicine.

Delivery system: Platforms: oil-in-water emulsions, cationic emulsions, microemulsions, microemulsion-hydrogel/in situ gel systems, liposomes, cubosomes, niosomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and core–shell nanoassemblies. - Payloads: cyclosporin A, difluprednate, flurbiprofen axetil, indomethacin, dorzolamide, fluconazole, dexamethasone, acetazolamide, timolol maleate, methazolamide, coenzyme Q10, and others. - Surface modification/targeting: cationic lipids (oleylamine, stearylamine, chitosan, DOTAP), mucoadhesive polymers (chitosan, Carbopol, thiolated PEG stearate, N-trimethyl chitosan), and core–shell lipid coatings. - Key design goals: reduce contact angle, improve wettability/spreading, prolong precorneal retention, enhance transcorneal penetration, and control drug release.

Approach: Review and synthesis of in vitro, ex vivo, in vivo, and clinical literature. Model systems include rabbit eyes, rabbit keratitis models, human conjunctival epithelial cells, and marketed/clinical products. Disease contexts include dry eye syndrome, inflammation, glaucoma, cataract, and ocular infection. As a review, it reports no primary experimental groups, n values, doses, or controls.

Key methods: No primary methods. The review discusses data generated by cited studies using: - Aqueous humor pharmacokinetics (AUC, Cmax, MRT). - Preocular retention and tear fluid drug levels. - Contact angle and spreading coefficient measurements. - Intraocular pressure (IOP) pharmacodynamics. - Corneal and sclera–retina tissue distribution. - In vitro drug release and stability testing. - Clinical trial and marketed product evaluations.

Key results: Typically <5% of a topically applied drug penetrates the cornea and sclera to reach intraocular tissue. - Tear turnover is about 16% per minute during waking hours; reflex lachrymation can increase tear flow up to 300 µl/min. - Optimal corneal permeability is associated with log D 2–3. - Cationic emulsions reduced contact angle versus saline: saline 70°, anionic emulsion 38°, cationic emulsion 21°; spreading coefficients were −47, −8.6, and −2.4 mN/m, respectively. - Difluprednate lipid emulsion showed 5.7-fold higher active metabolite concentration in aqueous humor at 1 h versus suspension. - Flurbiprofen axetil emulsion showed 6.7-fold higher AUC₀–₁₀h than oil solution. - Chitosan-coated indomethacin emulsion had 3.6- and 3.8-fold higher tear fluid drug levels at 0.5 and 0.75 h, and 1.5-fold longer residence than non-coated emulsion. - Dorzolamide in situ gel nanoemulsion lowered IOP for up to 8 h, versus 5 h for most formulations. - Cyclosporine A microemulsion Kelcogel system had approximately 3-fold greater AUC₀–₃₂h in cornea than traditional CyA emulsion and maintained therapeutic levels at 32 h. - Dexamethasone cubosomes increased AUC₀–₂₄₀min 1.8-fold versus Dex-Na phosphate eye drops and about 8-fold versus DEX suspension. - Acetazolamide niosomes doubled Cmax versus suspension and broadened peak from 80 to 120 min, with concentration remaining >13 µg. - Thiolated NLCs extended preocular residence up to 6 h and increased CyA in anterior chamber. - Chitosan oligosaccharide-coated NLCs increased transcorneal penetration 2.4-fold versus uncoated NLC. - Marketed products include Restasis, Refresh Dry Eye Therapy, Durezol, Cationorm, Lipimix, Soothe XP Emollient, and Tear Again; Cyclokat and Catioprost were in Phase III trials.

Interpretation: The authors conclude that lipid-based nanocarriers are promising for topical ocular drug delivery. They can prolong preocular residence, improve corneal penetration, enhance bioavailability of poorly soluble drugs, and reduce side effects. With further development, lipid-based nanocarriers could become a backbone of ocular drug delivery systems.

Limitations: Review article; no primary data, effect sizes, n values, doses, or controls. - Ocular barriers remain formidable; only a small fraction of drug reaches intraocular tissues. - Liposomes can be unstable, aggregate, fuse, and leak drug during storage. - SLNs may show burst release and require optimization. - Clinical translation is still limited for many carrier types; most data are preclinical or early clinical. - Scale-up, preservative-free formulation, quality control, and long-term stability remain challenges. - More comparative studies and clinical trials are needed to establish superiority over conventional eye drops.